| aOR | 95% CI | P |
---|---|---|---|
Gender | |||
 Male | Reference |  |  |
 Female | 0.88 | 0.78–1.00 | 0.05 |
Smoker | |||
 Never/Former | Reference |  |  |
 Current | 1.04 | 0.92–1.16 | 0.56 |
Age | |||
  < 65 | Reference |  |  |
 65 or older | 1.03 | 0.93–1.14 | 0.61 |
KPS | |||
  < 90 | Reference |  |  |
 90–100 | 0.94 | 0.84–1.04 | 0.23 |
 Not available | 0.97 | 0.59–1.59 | 0.9 |
Race | |||
 White | Reference |  |  |
 Other | 0.85 | 0.74–0.97 | 0.02 |
Comorbidity | |||
 0 | Reference |  |  |
 1–3 | 0.93 | 0.82–1.06 | 0.3 |
  > 3 | 0.91 | 0.78–1.06 | 0.21 |
Site | |||
 Oropharynx | Reference |  |  |
 Larynx | 0.87 | 0.75–1.00 | 0.05 |
 Other | 1 | 0.88–1.14 | 1 |
T staging | |||
 1–2 | Reference |  |  |
 3–4 | 1.15 | 1.04–1.27 | 0.005 |
N staging | |||
 0–1 | Reference |  |  |
 2–3 | 1.04 | 0.93–1.17 | 0.47 |
HPV | |||
 Negative | Reference |  |  |
 Positive | 0.82 | 0.72–0.94 | 0.005 |
Not available | 0.93 | 0.82–1.06 | 0.26 |
 Chemo | |||
 Cisplatin | Reference |  |  |
 Other | 1.12 | 0.98–1.27 | 0.1 |